Idiopathic pulmonary fibrosis: Nintedanib
![Feature image](https://healthsci.mcmaster.ca/wp-content/uploads/2023/07/ipf-nintedanib.jpg)
The effects, mechanism of action and clinical trials for nintedanib as a treatment for IPF.
Nintedanib is an approved pharmacological agent for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This video explains the effects, mechanism of action and clinical trials for nintedanib.
[Please complete our feedback form]
Demystifying Medicine, Education, Idiopathic pulmonary fibrosis (IPF)
Related News
News Listing
![](https://healthsci.mcmaster.ca/wp-content/uploads/2024/06/McCall-MacBain-International-Fellows-2024-1.png)
Daily News ➚
5 McMaster students named McCall MacBain International Fellows
Collaborations & Partnerships, Education, Funding
3 days ago
![](https://healthsci.mcmaster.ca/wp-content/uploads/2024/06/Hannah-Snyder-headshot-photo-1200x675-1.jpg)
Department of Pediatrics ➚
Behind the White Coat: A conversation with pediatric neurology resident Hannah Snyder
Education, Feature
6 days ago